Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
about
hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes.hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.Ivabradine (Corlanor) for Heart Failure: The First Selective and Specific I f Inhibitor.Acute on Chronic Ivabradine Overdose: a Case Report.Could ivabradine be a new treatment for the short QT syndrome?
P2860
Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
@en
type
label
Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
@en
prefLabel
Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
@en
P2093
P2860
P356
P1476
Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
@en
P2093
Gordon F Rushworth
Philippe Lambrakis
Stephen J Leslie
P2860
P356
10.1177/2042098610393209
P577
2011-02-01T00:00:00Z